Herpes Zoster Clinical Trial
Official title:
The Safety and Clinical Utilities of the Fluoroscopy-guided Cervical Epidural Approach Using the Contralateral Oblique View: a Prospective Observational Study
NCT number | NCT04774458 |
Other study ID # | 2021-0197 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 4, 2021 |
Est. completion date | August 31, 2022 |
Verified date | September 2022 |
Source | Asan Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the present study is to investigate the safety and clinical utility of contralateral oblique view for fluoroscopic guided cervical epidural access.
Status | Completed |
Enrollment | 439 |
Est. completion date | August 31, 2022 |
Est. primary completion date | July 28, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 79 Years |
Eligibility | Inclusion Criteria: - Patients who need an epidural space access at C6-7 or C7-T1 level - Patients who are expected to undergo cervical epidural block - Patients who are expected to undergo cervical epidural neuroplasty - 20 = age <80 - When obtaining informed consent voluntarily Exclusion Criteria: - Allergy to local anesthetics and contrast dye, and steroid - Use of anticoagulants or antiplatelet medication, coagulopathy - Infection at the insertion site - Neurological or psychiatric disorders - Prior spine instrumentation - Pregnancy - Not visible epidural space due to severe cervical spinal canal stenosis |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Asan medical center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Asan Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dural puncture event - major complication | whether a dural puncture event occurs or not during the cervical epidural access | Immediately after contrast medium administration during the procedure | |
Secondary | Other complications | intravascular entry, subdural entry, vasovagal reaction, spinal cord injury | Immediately after procedure | |
Secondary | Needling time | time to access the epidural space after skin insertion | Immediately after procedure | |
Secondary | First attempt success | whether an cervical epidural access is successful at once without any withdrawal of the needle or not | Immediately after procedure | |
Secondary | Total number of needle passes | A needle pass is considered as an advancement of the needle without any withdrawal. If the needle is re-advanced after a withdrawal, it is considered as an additional(second) needle pass. | Immediately after procedure | |
Secondary | Rate of success or failure | Success is defined when contrast medium spreads appropriately in epidural space after physician successfully access cervical epidural space. | Immediately after procedure | |
Secondary | Needle tip visualization | The clarity of the needle tip was subjectively graded as 1 (clearly visualized without ambiguity), 2 (poorly visualized or visualized with effort), or 3 (not visualized). | One day after the procedure | |
Secondary | Needle tips location | Location of the needle tip was defined as being significantly before the VILL(Ventral interlaminar line) (-2), just before the VILL (-1), on the VILL (0), just after the VILL (+1), or significantly after the VILL (+2) | One day after the procedure | |
Secondary | False positive/negative loss of resistance | False positive: Not reaching epidural space despite feeling loss of resistance/ false negative: Reaching epidural space despite not feeling loss of resistance | Immediately after procedure | |
Secondary | Post-procedural complication | epidural hematoma, spinal cord injury, infection, abscess, facial flushing, post-dural puncture headache | Up to one month after the procedure | |
Secondary | Radiation dose (cGy) | Radiation dose (cGy) | Immediately after procedure | |
Secondary | Numerical rating scales (NRS) | One month after the procedure, the pain intensity is assessed using a numeric rating scale (0: no pain, 10: unbearable pain). | One month after the procedure | |
Secondary | Global perceived effect (GPE) | One month after the procedure, Patient satisfaction is assessed using global perceived effects on a 7-point scale (GPE). (1: very dissatisfied, 7: very satisfied) | One month after the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03120364 -
Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
|
Phase 3 | |
Completed |
NCT01165203 -
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
|
Phase 2 | |
Recruiting |
NCT06088745 -
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
|
Phase 3 | |
Completed |
NCT01385566 -
A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
|
Phase 1 | |
Completed |
NCT01137669 -
ZOSTAVAX® in Renal Transplant Patients
|
Phase 1 | |
Completed |
NCT01911065 -
T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
|
Phase 4 | |
Completed |
NCT00550745 -
ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
|
Phase 4 | |
Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
Completed |
NCT00231816 -
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
|
Phase 3 | |
Completed |
NCT02852876 -
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
|
Phase 1 | |
Completed |
NCT05082688 -
Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)
|
Phase 2 | |
Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
Active, not recruiting |
NCT04091451 -
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles
|
Phase 3 | |
Completed |
NCT02519855 -
Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
|
Phase 3 | |
Completed |
NCT04523246 -
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
|
Early Phase 1 | |
Completed |
NCT05047770 -
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
|
Phase 3 | |
Completed |
NCT03314103 -
Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age
|
Phase 3 | |
Completed |
NCT01527370 -
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
|
Phase 3 | |
Completed |
NCT01954251 -
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
|
Phase 3 |